🇺🇸 FDA
Patent

US 9018201

Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) for use in treatment of diseases associated with a PTEN deficiency

granted A61KA61K31/5025A61K31/5377

Quick answer

US patent 9018201 (Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) for use in treatment of diseases associated with a PTEN deficiency) held by BIOMARIN PHARMACEUTICAL INC. expires Mon Apr 23 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
BIOMARIN PHARMACEUTICAL INC.
Grant date
Tue Apr 28 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 23 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
21
CPC classes
A61K, A61K31/5025, A61K31/5377, A61K45/06, A61P